Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

92
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
92
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.0K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

231
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
231

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small airway dysfunction: a key predictor of exacerbation risk in adolescents with mild, well-controlled asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Beyond eosinophils: redefining asthma exacerbations in the biologic era.

The Lancet. Respiratory medicine·2026
Same author

HIgh versus STAndard blood Pressure target in hypertensive high-risk patients undergoing elective major abdominal surgery: the HISTAP multicenter randomized clinical trial.

Intensive care medicine·2026
Same author

Phenotyping of Obstructive Sleep Apnea Syndrome and Association with Cognitive Impairment, a Real-Life Study.

Biomedicines·2026
Same author

Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.

Biomedicines·2026
Same author

Artificial intelligence and the future of telemonitoring in home mechanical ventilation.

ERJ open research·2026

Related Experiment Video

Updated: Dec 28, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K

Adherence to omalizumab: A multicenter "real-world" study.

Raffaele Campisi1, Claudia Crimi1, Rossella Intravaia2

  • 1Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Catania, Italy.

The World Allergy Organization Journal
|February 22, 2020
PubMed
Summary
This summary is machine-generated.

High adherence to omalizumab in severe asthma patients was observed in a real-world study. Good adherence correlated with improved asthma control and fewer exacerbations, highlighting its importance for treatment effectiveness.

Keywords:
AdherenceEfficacyOmalizumabReal-worldSevere asthma

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.7K

Related Experiment Videos

Last Updated: Dec 28, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.7K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Real-world evidence studies

Background:

  • Medication adherence is critical for managing severe asthma, yet adherence to omalizumab in real-world settings remains understudied.
  • Non-adherence to asthma medications leads to significant clinical and economic burdens.

Purpose of the Study:

  • To assess real-world adherence rates to omalizumab in patients with severe asthma.
  • To evaluate the effectiveness of omalizumab treatment in relation to patient adherence.

Main Methods:

  • A retrospective, observational, multicenter study analyzed omalizumab dosing, timing, and treatment duration.
  • Adherence was defined as missing <10% of doses; effectiveness was measured by asthma exacerbations, hospitalizations, Asthma Control Test (ACT), and FEV1.
  • Logistic regression identified factors associated with adherence.

Main Results:

  • 161 patients were analyzed; 90.7% demonstrated good adherence to omalizumab.
  • Adherence was 100% in patients treated for over 4 years.
  • Significant improvements in ACT scores (p=0.043) and reduced asthma exacerbations (p=0.049) were observed in adherent patients.
  • Increasing age, better ACT scores, and 14-day dosing intervals were linked to higher adherence.

Conclusions:

  • High adherence to omalizumab is achievable in real-world clinical practice.
  • Omalizumab adherence is associated with improved asthma control and treatment outcomes.